Main duct type intraductal papillary mucinous neoplasm (IPMN) is a mucin-producing pancreatic neoplasm characterized by diffuse or segmental dilatation of the main pancreatic duct (duct of Wirsung). Main duct IPMNs account for approximately 25-30% of all IPMNs and carry the highest malignancy risk, with invasive carcinoma rates reaching 40-60%. Endoscopic visualization of mucin extruding from the major papilla ('fish-mouth papilla') is pathognomonic. Surgical resection is the standard treatment.
Age Range
60-80
Peak Age
70
Gender
Male predominant
Prevalence
Uncommon
Main duct IPMN is characterized by papillary proliferation of neoplastic cells arising from the pancreatic duct epithelium with excessive mucin production. Mucin accumulation causes progressive dilatation of the main pancreatic duct; the duct diameter exceeds 5 mm and frequently surpasses 10-15 mm. This dilatation appears as a characteristic tubular cystic structure on imaging. Mucin production may protrude from the papilla of Vater, creating the 'fish-mouth' appearance at endoscopy. Pathophysiologically, it follows an adenoma-dysplasia-carcinoma sequence, progressing from low-grade dysplasia to high-grade dysplasia and invasive carcinoma. Mural nodules represent solid components growing into the duct lumen, and the presence of enhancing mural nodules strongly suggests high-grade dysplasia or invasive carcinoma. Duct wall thickening and enhancement reflect neoplastic cell proliferation and neovascularization on imaging.
Visualization of mucin extruding from the major papilla at endoscopy — the papilla appears patent and bulging with mucinous material seeping through. This finding is pathognomonic for main duct IPMN and no other pancreatic cystic neoplasm demonstrates this feature. On MRCP, it may be indirectly reflected as blunt termination of the dilated distal duct at the papillary level.
Diffuse or segmental dilatation of the main pancreatic duct, diameter >5 mm (frequently 10-30 mm range). The duct shows smooth contours with a tubular dilatation pattern. Involvement may extend along the entire duct length or be segmental.
Report Sentence
Diffuse/segmental dilatation of the main pancreatic duct is observed, measuring [X] mm in diameter; this finding is consistent with main duct type IPMN.
Enhancing solid mural nodule within the dilated duct. The nodule is reliably detected when >5 mm in size. It shows prominent enhancement in the arterial phase and is the most reliable indicator of high-grade dysplasia or invasive carcinoma.
Report Sentence
An enhancing mural nodule measuring [X] mm is observed within the dilated main pancreatic duct; this finding should be considered a high-risk stigma for high-grade dysplasia or invasive neoplasm.
On T2-weighted sequences, the main pancreatic duct shows markedly hyperintense tubular dilatation due to mucin content. The high water content of mucin creates bright signal on T2. The duct wall may be thin and smooth or thickened.
Report Sentence
On T2-weighted sequences, the main pancreatic duct demonstrates markedly hyperintense tubular dilatation, consistent with mucinous content.
MRCP clearly demonstrates diffuse or segmental dilatation of the main pancreatic duct. The dilated duct can be traced to the papilla of Vater. Communication with branch ducts is assessed. Presence of duct interruption or complete obstruction suggests malignancy. When MRCP is performed with secretin, mucin excretion and duct dynamics can be evaluated.
Report Sentence
MRCP demonstrates diffuse/segmental dilatation of the main pancreatic duct reaching [X] mm in diameter; the duct is traceable to the papilla of Vater, consistent with main duct type IPMN.
Thinning and atrophy of the pancreatic parenchyma proximal to the dilated segment. Develops as a result of acinar cell loss and fibrosis due to chronic obstruction. Parenchymal atrophy indicates that the lesion is causing chronic and hemodynamically significant obstruction.
Report Sentence
Pancreatic parenchymal atrophy and fatty infiltration are observed proximal to the dilated duct segment, consistent with chronic obstruction.
On diffusion-weighted imaging, mural nodules may demonstrate diffusion restriction (hyperintense on high b-value, low signal on ADC map). This finding indicates increased cellularity and suggests malignant transformation.
Report Sentence
Diffusion restriction is observed in the mural nodule within the dilated duct, suggesting increased cellularity and possible malignant transformation.
On transabdominal US, the main pancreatic duct is visualized as anechoic/hypoechoic tubular dilatation. Hyperechoic mucin plugs or isoechoic-hypoechoic mural nodules may be seen within the duct. However, US sensitivity is limited compared to CT/MRI.
Report Sentence
On transabdominal US, the main pancreatic duct appears dilated, measuring [X] mm in diameter.
Criteria
Diffuse dilatation of the entire main pancreatic duct from head to tail (>5 mm). Mucin accumulation and homogeneous widening throughout the entire duct length.
Distinct Features
May require total pancreatectomy due to involvement of the entire duct. Carries higher malignancy risk compared to segmental type. Multifocal dysplasia is common.
Criteria
Focal dilatation in a limited segment of the main pancreatic duct. May be localized to the head, body, or tail segment. Bounded by normal duct segments.
Distinct Features
Can be surgically treated with segmental pancreatectomy (distal pancreatectomy or Whipple procedure). Better prognosis compared to diffuse type. Frozen section margin assessment is critical.
Criteria
Development of invasive carcinoma arising from main duct IPMN. Enhancing solid component, mass extending beyond the duct, vascular invasion, or distant metastasis findings.
Distinct Features
Two histologic subtypes: tubular type (resembles pancreatic ductal adenocarcinoma, poor prognosis) and colloid type (mucinous pools, better prognosis). Tubular type accounts for ~60%, colloid type ~40%. Colloid type characteristically shows T2-hyperintense mucinous pools.
Criteria
Four epithelial subtypes: gastric, intestinal, pancreatobiliary, and oncocytic. Subtyping is done by pathological examination, although imaging findings may provide clues.
Distinct Features
Intestinal type is most common in main duct IPMN and is associated with colloid invasive carcinoma (better prognosis). Pancreatobiliary type is associated with tubular invasive carcinoma (poor prognosis). Gastric type is more common in branch duct IPMN. Oncocytic type is rare.
Distinguishing Feature
Ductal adenocarcinoma appears as a hypovascular solid mass causing obstructive pancreatic duct dilatation; however, abrupt duct cutoff at the mass ('double duct sign') is typical. In IPMN, gradual dilatation due to intraluminal mucin is seen, and solid mass is not dominant.
Distinguishing Feature
Mucinous cystic neoplasm (MCN) presents as a macrocystic lesion with NO communication with the pancreatic duct; it occurs almost exclusively in women and is located in the body-tail. Main duct IPMN is directly visualized as pancreatic duct dilatation with direct duct communication. Ovarian-type stroma is pathognomonic for MCN.
Distinguishing Feature
Mixed type IPMN shows both main duct dilatation and branch duct cysts simultaneously. Pure main duct IPMN lacks branch duct cysts and shows only tubular main duct dilatation. MRCP is the most valuable modality for this distinction.
Distinguishing Feature
Pseudocyst appears as a thin smooth-walled, homogeneously fluid-density encapsulated collection associated with pancreatitis history. Duct communication may exist but no mural nodules or solid components are present within the cyst. In main duct IPMN, the duct itself is dilated and may contain mural nodules, and pancreatitis history is not required.
Urgency
urgentManagement
surgicalBiopsy
Not NeededFollow-up
specialist-referralMain duct IPMN carries a surgical resection indication due to high malignancy risk (40-60% invasive carcinoma). According to Sendai/Fukuoka international consensus guidelines, main duct diameter >10 mm or presence of enhancing mural nodules is considered 'high-risk stigmata' and surgery is recommended. In patients unfit for surgery, EUS-FNA tissue sampling is considered. Preoperative EUS mural nodule assessment and fluid analysis (CEA, cytology) aids decision-making. Surgical type is determined by lesion location: head→Whipple, body-tail→distal pancreatectomy, diffuse→total pancreatectomy.
Main duct IPMN is an indication for surgical resection due to high malignancy risk (40-90%). The revised Fukuoka guidelines classify main duct IPMN as high-risk stigmata. Mural nodules, duct diameter >10mm, and high-grade dysplasia on cytology support surgical decision.